In a mouse model of lung cancer driven by EGFR T790M/L858R mutant, treatment with an antibody MM-121, which blocks ligand-induced activation of ErbB3 and cetuximab, induced durable tumour regression [165]. Here, EGFR is linked to neoplasm.